| | ABC News Coverage: Catalent’s COVID-19 Partnership with Moderna |
|
| In a recent news segment, ABC News showcased the processes used in the manufacture of COVID-19 vaccines, and the contribution made by employees at Catalent’s facility in Bloomington, Indiana. |
|
| | | Catalent Chair and CEO Interviewed by Financial Times |
|
| How will the pandemic alter the future of pharmaceutical manufacturing? During the Financial Times’ recent US Pharma and Biotech Summit, John Chiminski, Catalent’s Chair and CEO, discussed some valuable lessons learned.
John suggested that broader and deeper collaboration, new ways of working, and proactive investment will intersect with revolutionary manufacturing and distribution approaches, and that an unprecedented pace of innovation, AI, and precision medicines will become increasingly commonplace. |
|
| | | | | Catalent is Proud to Support Many High-Profile COVID-19 Programs
Catalent has been awarded more than 80 COVID-19-related compounds including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. Catalent is on track to deliver over one billion COVID-19 vaccine and treatment doses in 2021.
|
|
| | | | | Catalent Biologics Experts Discuss Bioprocessing 4.0 in GEN
In Genetic Engineering & Biotechnology News, Catalent Biologics experts discuss the technologies available to help deliver novel biotherapeutics more quickly. Read the article.
Experts also discussed the ways digital manufacturing technologies can support the rising demand for process intensification. Read the article.
| | Find Out More | | |
|
| Manufacturing Chemist Interviews Catalent Biologics Expert
Growth in the global bispecific antibody market has accelerated in recent years. Manufacturing Chemist interviewed Catalent Biologics’ Gregory Bleck, Ph.D., Vice President of Research and Development, to discover more about the applications for these innovative therapies, and their pros and cons.
| | Find Out More | | |
|
| Catalent Experts Discuss QbD in Pharmaceutical Technology
Experts discuss the ways that a quality-by-design (QbD) approach can help address excipient variability and other critical quality attributes, in Pharmaceutical Technology.
| | Find Out More | | |
|
| Catalent Announces New Chief Financial Officer
Thomas Castellano was recently promoted to Senior Vice President and Chief Financial Officer. Prior to his promotion he served as Catalent’s Global Vice President of Operational Finance, providing finance partnership on strategic execution across the company’s business units, and as a member of Catalent’s Executive Leadership Team.
| | Find Out More | | |
|
| Join Our Experts at Live Virtual Events to Hear the Latest on COVID-19 and Technology Development Programs |
|
| BPI Theatre at BIO Digital | Virtual Conference | June 14 - 18
Dr. Bleck will present “Tailoring the Cell Line Development Process to the Specific Molecule and the Program Goals.”
Webinar | Use of PBPK Modeling for Predicting and Optimizing Controlled Release Dosage Forms | June 14
Experts share how dissolution tools and PBPK modeling can help evaluate whether a molecule is suitable for controlled release applications, and predict the effects of release rate on in vitro performance.
Webinar | The Post-COVID Pipeline Takes Shape – New Vaccines and Drugs During the mRNA Revolution | June 15
Hosted by Endpoints News, experts including Catalent’s Karen Flynn, President, Biologics and Chief Commercial Officer, will discuss the follow-up drugs and vaccines currently being produced to tackle COVID-19 variants.
Next Gen: What’s Beyond the Leading Edge of Biotech and Pharma? | Virtual | June 22-23
Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy will join a panel session titled, “What’s Next in Gene Therapy?”, Behzad Mahdavi, Ph.D., Vice President, Open Innovation, Catalent Biologics and Cell & Gene Therapy, will present “Manufacturing of New Modalities: New Opportunities Come with New Challenges”, and Mike Riley, Region President, North America, Catalent Biologics, will take part in an exclusive interview session.
HPAPI Summit USA | Virtual Conference | June 22 – 24
Andy Maitland, Director, Operations and Supply Chain, Catalent, will present “High Potency Containment from Early Stage to Commercial Scale Micronization.”
Webinar | Aligning Clinical Supply Strategy with the Target Product Profile for your Clients | June 22
Designed specifically for consultants, this webinar will cover the key clinical supply strategy considerations that are impacted by the target product profile, and the real-world application of clinical supply management theory.
Outsourcing in Clinical Trials / Clinical Trial Supply Asia | Virtual Conference | June 29 - 30
Meet with Catalent at Outsourcing in Clinical Trials Asia. Daniel Gao, General Manager, Catalent, will present “Understanding the Impact of Primary Packaging Decisions on Clinical Supply Success”.
CRS Annual Meeting | Virtual Conference | July 25-29
Catalent’s Lisa Caralli, Director, Science & Technology presents “Strategies to Optimize the Dose Design Process to Create Better Treatments” and will use case studies to show how the right guidance, at the right time, can help drug developers create better treatments.
|
| A Catalyst in Drug Development |
|
| Christin Hollis, Ph.D.
Product Development Manager, Winchester, Kentucky |
|
| Dr. Hollis specializes in large scale/late-stage oral dosage form drug development. She collaborates with clients and internal technical service teams developing robust processes by implementing Quality by Design (QbD) approaches, that are optimized and scalable for large-scale commercialization. Dr. Hollis received a bachelor’s degree in chemical engineering, and a doctorate in pharmaceutical science, both from the University of Kentucky. Her published works include six peer-reviewed articles, a patent, and several executive summaries and case studies. |
|
|
|
| | | | Consumer Health
- Executive Summary: “Immune-Health Supplement Drivers: Trends and Innovation in Ingredients and Delivery”– Experts from Nutritional Business Journal and Catalent discuss opportunities to incorporate immune health formulations that have strong scientific backing into brands.
- Webinar: “Where to Innovate in OTC?” - In this webinar, Catalent partnered with NielsenIQ to suggest new insights to re-establish growth in the OTC market through innovation.
- Webinar: “The Emergence of Inner Beauty” - Inner Beauty, also known as Beauty Nutrition, is one of the fastest growing categories in the nutritional supplements market. In this webinar, Catalent experts explore the market trends and how to bring those trends to life.
- Webinar: “The Emergence of Outer Beauty” - In this webinar, Catalent experts explore the trends, innovations, and the lasting impact that topical beauty will have in the future.
|
|
| | | Oral Development and Manufacturing - Explore Catalent’s corporate headquarters located in Somerset, New Jersey. This location houses our state-of-the-art laboratory, clinical, and commercial manufacturing for oral dose forms in addition to being the Center of Excellence for Highly Potent Active Pharmaceutical Ingredients. View now: https://www.catalent.com/site-tours/somerset-360-virtual-tour/
- View the Swindon, U.K., facility that is the manufacturing center for the Zydis® Orally Disintegrating Tablet (ODT) platform. Equipped with high-speed manufacturing suites, the site produces approximately 1.2B doses per year and supports both Rx and OTC products, including potent and controlled substances. View now: https://www.catalent.com/site-tours/swindon-uk-site-tour-video/
|
|
| | | Biologics Development and Manufacturing - Take a virtual tour of our Madison, Wisconsin, biologics drug substance development and manufacturing facility. Madison is Catalent’s Center of Excellence for cell line development and home to GPEx® cell line development technology. View now: https://www.catalent.com/site-tours/madison-site-tour-video/
| | | Cell and Gene Therapies - Explore Catalent’s Harmans, Baltimore, clinical through commercial manufacturing facility for gene therapies. The state-of-the-art, FDA-licensed facility, houses 10 CGMP manufacturing suites, including fill/finish, and also comprises central services labs, testing labs, and acts as our central warehouse and supply chain hub for Catalent Gene Therapy. View now: https://www.catalent.com/site-tours/harmans-bwi-360-virtual-tour/
|
| We are the Catalyst for your Success.
Join Us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites including: Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri. Visit www.catalent.com/careers for more information. |
|
| | |
|
Every brand has a challenge. We have a solution. |
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here. For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2021, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
